Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NuVasive, Inc.    NUVA

NUVASIVE, INC.

(NUVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • With an expected P/E ratio at 35.35 and 25.53 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The underlying tendency is negative on the weekly chart below the resistance at 56.68 USD
Ratings chart
Sector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalisation (M$)Investor Rating
NUVASIVE, INC.-39.32%2 447
MEDTRONIC PLC-20.77%120 468
BAXTER INTERNATIONAL INC.-4.58%40 470
HOYA CORPORATION-2.44%35 360
TERUMO CORPORATION-0.06%25 583
DEXCOM, INC.20.22%24 086
ZIMMER BIOMET HOLDINGS-36.57%19 622
SARTORIUS STEDIM BIOTECH15.78%17 477
AMERISOURCEBERGEN CORPORATI..-3.81%16 838
SYSMEX CORPORATION-0.13%15 447
ALIGN TECHNOLOGY, INC.-36.55%13 942
STERIS PLC-14.88%11 004
WEST PHARMACEUTICAL SERVICE..-6.15%10 412
FISHER & PAYKEL HEALTHCARE ..11.11%9 871
LEPU MEDICAL TECHNOLOGY (BE..0.60%9 570
DENTSPLY SIRONA INC.-32.97%8 399
More Results
Financials (USD)
Sales 2020 1 210 M
EBIT 2020 189 M
Net income 2020 69,9 M
Debt 2020 339 M
Yield 2020 -
P/E ratio 2020 35,3x
P/E ratio 2021 25,5x
EV / Sales2020 2,30x
EV / Sales2021 2,09x
Capitalization 2 447 M
Upcoming event on NUVASIVE, INC.
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes